Journal
IMMUNOTHERAPY
Volume 10, Issue 15, Pages 1293-1302Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2018-0116
Keywords
advanced melanoma; efficacy; meta-analysis; PD-1 inhibitors; safety
Categories
Ask authors/readers for more resources
Aim: We conducted a meta-analysis to systematically review the efficacy and safety of programmed cell death 1 (PD-1) inhibitors for advanced melanoma. Study design: The relevant studies of the randomized controlled trials in melanoma patients treated with PD-1 inhibitors were retrieved and the systematic evaluation was conducted. Databases were searched till June 2018. Results: PD-1 inhibitors significantly improved the progression-free survival, overall survival and overall response rate in patients with advanced melanoma. Progression-free survival, overall survival and overall response rate did not vary significantly according to PD-L1 status, V-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations and type of drug, but varied significantly by control therapy. PD-1 inhibitors were associated with a decreased risk of adverse events compared with ipilimumab, but an increased risk of immune-related events compared with chemotherapy. Conclusion: The PD-1 inhibitors-containing therapy was efficacious in treating advanced melanoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available